Currently, two other phase 2 trials are ongoing to evaluate the efficacy of everolimus in patients with refractory, recurrent, and locally advanced HNSCC and to study the correlation of everolimus treatment with tumor- and patient-associated markers of the EGFR-mTOR pathway. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.